Person: ŞEKER, MESUT
8 results
Search Results
Now showing 1 - 8 of 8
Publication Open Access Scalp recurrence of cholangiocarcinoma after curative hepatectomy: A report of two cases(2017-12-01) Kunduz, ENVER; Serin, Kursat Rahmi; Şeker, MESUT; KUNDUZ, ENVER; ŞEKER, MESUTCholangiocarcinomas are the second most common primary liver malignancies. The lymphatics are the common route of metastatic spread for cholangiocarcinomas. The most frequent sites of metastasis are the liver, abdominal lymph nodes, peritoneum and lungs. Cutaneous metastasis of cholangiocarcinoma is rare, and most commonly occurs following percutaneous biliary drainage. Brain or skull metastases from this tumor are uncommon. However, these rare metastatic lesions may occasionally be the first disease manifestation, although scalp recurrence following curative treatment is uncommon. We herein present the cases of two patients with cholangiocarcinoma, who were evaluated as resectable based on the criteria for cholangiocarcinoma resectability, and developed scalp recurrence following curative hepatectomy. Therefore, although scalp recurrence is a rare occurrence following curative treatment for cholangiocarcinoma, metastases should be included in the differential diagnosis.Publication Open Access Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study(2022-01-01T00:00:00Z) YASİN, Ayşe İrem; Aydin, Sabin Goktas; SÜMBÜL, BİLGE; KORAL, LOKMAN; ŞİMŞEK, MELİH; Geredeli, Caglayan; Ozturk, Akin; Perkin, Perihan; Demirtas, Derya; Erdemoglu, Engin; HACIBEKİROĞLU, İLHAN; Cakir, Emre; Tanrikulu, Eda; Coban, Ezgi; Ozcelik, Melike; Celik, Sinemis; Teker, Fatih; AKSOY, ASUDE; Firat, Sedat T.; Tekin, Omer; Kalkan, Ziya; Turken, Orhan; Oven, Bala B.; Dane, Faysal; Bilici, Ahmet; Isikdogan, Abdurrahman; ŞEKER, Mesut; TÜRK, HACI MEHMET; Gumus, Mahmut; YASİN, AYŞE İREM; SÜMBÜL, BİLGE; ŞİMŞEK, MELİH; ŞEKER, MESUT; TÜRK, HACI MEHMETAim: To compare the seropositivity rate of cancer patients with noncancer controls after inactive SARS-CoV-2 vaccination and evaluate the factors affecting seropositivity. Method: Spike IgG antibodies against SARS-CoV-2 were measured in blood samples of 776 cancer patients and 715 noncancer volunteers. An IgG level ≥50 AU/ml is accepted as seropositive. Results: The seropositivity rate was 85.2% in the patient group and 97.5% in the control group. The seropositivity rate and antibody levels were significantly lower in the patient group (p < 0.001). Age and chemotherapy were associated with lower seropositivity in cancer patients (p < 0.001). Conclusion: This study highlighted the efficacy and safety of the inactivated vaccine in cancer patients.Publication Open Access Evaluation of Kidney Function in Patients on Chemotherapy(2021-04-01T00:00:00Z) Haziyev, Elgun; GÜRSU, Meltem; ŞEKER, Mesut; ELÇİOĞLU, Ömer Celal; ARTAN, AYŞE SERRA; ALİYEV, Altay; TÜRK, HACI MEHMET; DEMİR, Tarık; TOPRAK, ALİ; KAZANCIOĞLU, Rümeyza; GÜRSU, MELTEM; ŞEKER, MESUT; ELÇİOĞLU, ÖMER CELAL; ARTAN, AYŞE SERRA; ALİYEV, ALTAY; TÜRK, HACI MEHMET; DEMİR, TARıK; TOPRAK, ALİ; KAZANCIOĞLU, RÜMEYZAObjective: We aimed to study whether long-term kidney function would be affected by different chemotherapy regimens in patients with malignancy.Publication Open Access Platelet to lymphocyte ratio is associated with tumor localization and outcomes in metastatic colorectal cancer(2021-11-01T00:00:00Z) Acikgoz, Ozgur; Cakan, Burcin; DEMİR, Tarık; Bilici, Ahmet; Oven, Bala Basak; Hamdard, Jamshid; Olmuscelik, Oktay; Olmez, Omer Fatih; ŞEKER, Mesut; Yildiz, Ozcan; DEMİR, TARıK; ŞEKER, MESUTThe aim of this study was to investigate the predictive and prognostic value of PLR, and the relationship between PLR and tumor localization. A total of 229 patients with de-novo metastatic CRC were retrospectively analyzed. The cutoff value for PLR was defined by the receiver operating characteristic (ROC) curve analysis and threshold value of 196.5 as best cut-off value was found. The higher rate of BRAF mutation was significantly detected for patients with PLRhigh (> 196.5) compared to those with PLRlow (<= 196.5) (P = .001). PLR was significantly higher in tumors located on the right colon (P = .012). PLR, tumor localization, the presence of surgery for primary tumor, the presence of curative surgery, the presence of metastasectomy for progression-free survival (PFS) and PLR, gender, BRAF mutation, tumor localization, the presence of surgery for primary tumor, the presence of metastasectomy for overall survival (OS) were found to be prognostic factors by univariate analysis. Multivariate analysis showed that PLR, the presence of curative surgery and the presence of metastasectomy for both PFS and OS were found to be independent prognostic factors. Moreover, a logistic regression analysis indicated that PLR and tumor localization were found to be an independent factors for predicting response to systemic treatment (P P = .023 respectively). Our results showed that pretreatment PLR was readily feasible and simple biomarker predicting response to treatment and survival, in addition it was significantly associated with tumor localization.Publication Open Access Prognostic Significance of Metastatic Lymph Node Ratio in Patients with pN3 Gastric Cancer Who Underwent Curative Gastrectomy.(2019-01-01T00:00:00Z) Bilici, A; Selcukbiricik, F; Seker, MESUT; Oven, BB; Olmez, OF; Yildiz, O; Olmuscelik, O; Hamdard, J; Acikgoz, O; Cakir, A; Kapran, Y; Balik, E; Oncel, M; ŞEKER, MESUTBackground: Lymph node involvement is an important prognostic factor in patients with gastric cancer. The aim of this study was to determine the prognostic significance of metastatic lymph node ratio (MLNR) and compare it to the number of lymph node metastasis in pN3 gastric cancer. Methods: We retrospectively analyzed 207 patients with pN3 gastric cancer who had undergone radical gastrectomy. Prognostic factors and MLNR were evaluated by univariate and multivariate analysis. Results: An MLNR of 0.75 was found to be the best cut-off value to determine the prognosis of patients with pN3 gastric cancer (p = 0.001). The MLNR was significantly higher in patients with large-sized and undifferentiated tumors, vascular, lymphatic and perineural invasion, and total gastrectomy. In multivariate analysis, MLNR (p = 0.041), tumor differentiation (p = 0.046), and vascular invasion (p = 0.012) were found to be independent prognostic factors for disease-free survival, while both MLNR (p < 0.001) and pN stage (p = 0.002) were independent prognostic indicators, as was tumor size, for overall survival. There was significant difference with respect to the recurrence patterns between MLNR groups. Lymph node and peritoneal recurrences were significantly higher in patients with MLNR > 0.75 compared to the MLNR < 0.75 group (p < 0.05). However, recurrence patterns were similar between pN3a and pN3b. Conclusion: Our results showed that MLNR was a useful indicator to determine the prognosis and recurrence patterns of patients with radically resected gastric cancer. Moreover, MLNR is a beneficial and reliable technique for evaluating lymph node metastasis.Publication Open Access The efficacy of BNT162b2 (Pfizer-BioNTech) and CoronaVac vaccines in patients with cancer(2022-05-01T00:00:00Z) ŞİMŞEK, MELİH; Yasin, Ayse; BEŞİROĞLU, MEHMET; TOPÇU, Atakan; SUCUOĞLU İŞLEYEN, ZEHRA; ŞEKER, Mesut; TÜRK, HACI MEHMET; ŞİMŞEK, MELİH; BEŞİROĞLU, MEHMET; TOPÇU, ATAKAN; SUCUOĞLU İŞLEYEN, ZEHRA; ŞEKER, MESUT; TÜRK, HACI MEHMETAlthough vaccination is efficacious and prevents infection in the general population, there is limited data about Coronavirus disease-19 (Covid-19) occurrence after vaccination in cancer patients. It was aimed to evaluate the efficacy of BNT162b2 (Pfizer-BioNTech) and CoronaVac vaccines against Covid-19 in patients with cancer. In this single-center, retrospective, cross-sectional, and descriptive study, the data of cancer patients referred to the medical oncology clinic of a university hospital were analyzed. The sample of the study consisted of cancer patients who had Covid-19 or were vaccinated against Covid-19. A total number of 2578 patients were included in the study. Of the patients, 2000 have never been infected with severe acute respiratory syndrome coronavirus and 578 patients have had a positive reverse-transcription polymerase chain reaction (RT-PCR) for Covid-19. It was found that 2094 patients (81.2%) were fully vaccinated, and 484 patients (18.8%) did not receive full-dose vaccination. A statistically significant difference in Covid-19 occurrence was found between the patients who had full-dose vaccination or not (p = 0.000). In in-group comparisons of full-dose vaccinated patients, while no difference was observed between two doses of BNT162b2 (Pfizer-BioNTech) and three doses of CoronaVac (p = 0.432), a statistically significant difference was observed between all other groups (p < 0.005). When the data of 578 patients who experienced Covid-19 was analyzed, a statistically significant difference was observed between the groups who were full-dose vaccinated and those who were not (p = 0.000). It is recommended that this vulnerable patient group should be prioritized in vaccination programs, and full-dose vaccination (at least two doses of vaccines) should be completed as soon as possible.Publication Open Access Primitive Neuroectodermal Tumor of the Testis(2021-11-01T00:00:00Z) DEMİR, Tarık; ALİYEV, Altay; ŞEKER, Mesut; ERSÖZ, CEVPER; ÇOBAN, GANİME; TÜRK, HACI MEHMET; DEMİR, TARıK; ALİYEV, ALTAY; ŞEKER, MESUT; ERSÖZ, CEVPER; ÇOBAN, GANİME; TÜRK, HACI MEHMETA 21-year male presenting with left testicular mass and retroperitoneal lymphadenopathy underwent radical orchiectomy; and his pathological examination showed a mixed germ cell tumor composed of primitive neuroectodermal tumor mixed with mature teratoma. Six cycles of IE (ifosfamide, etoposide) and VAC (vincristine, doxorubicin, cyclophosphamide) chemotherapy were given after sperm preservation. He then underwent retroperitoneal lymph node dissection (RPLND). No tumor was detected in the removed lymph nodes, and all lymph nodes were reported as showing reactive changes.Publication Open Access Cutaneous Involvement of Lung Adenocarcinom(2018-10-01) Cengiz, FATMA PELİN; Tosuner, ZEYNEP; Sonmez, BERKANT; Seker, MESUT; Emiroglu, NAZAN; Turk, HACI MEHMET; Onsun, NAHİDE; CENGİZ, FATMA PELIN; TOSUNER, ZEYNEP; SÖNMEZ, BERKANT; ŞEKER, MESUT; EMİROĞLU, NAZAN; TÜRK, HACI MEHMET; ONSUN, NAHIDE